Literature DB >> 12827240

Genetic variation of the platelet- surface integrin GPIIb-IIIa (PIA1/A2-SNP) shows a high association with Type 2 diabetes mellitus.

D Tschoepe1, B Menart, P Ferber, C Altmann, M Haude, B Haastert, P Roesen.   

Abstract

AIMS/HYPOTHESIS: The gene encoding the beta(3)-subunit (GPIIIa) of the platelet alpha(2)beta(3)-integrin (fibrinogen receptor) shows a polymorphism PlA1/A2 with the A2 allele putatively associated with an increased risk of acute ischaemic events. This study investigated whether Type 2 diabetes as a particular macrovascular risk factor associates with the thrombogenic PIA2 genotype.
METHODS: The PlA genotype was determined in 112 consecutive Type 2 diabetic patients additionally classified according to the presence of macrovascular disease. Forty-four non-diabetic patients with angiografically documented cardiovascular disease (CAD/ AMI) and a further 59 non-diabetic subjects with no angiografical signs of CAD were investigated as genomic background control (n=103). PIA-genotyping was carried out by standard restriction fragment length analysis (RFLA) of PCR amplified lymphocyte template DNA.
RESULTS: The overall allelic PlA2- prevalence accounted to 34.8% (39/112) in diabetic patients as compared to 14.6% (15/103) in non-diabetic patients [OR 3.1 (1.6-6.1), p<0.01]. This odds ratio increased to 7.0 (2.5-19.7), (p<0.01) in subjects free of criteria of macrovascular disease. In non-diabetic control subjects without CAD there was an allelic PIA2 frequency of 10.2% (6/59) as compared to 20.5% (9/44) in patients with CAD and a history of AMI being less than either diabetes subgroup. The PIA2 prevalence in the subgroup of diabetes patients with macrovascular complications did not differ from the respective value in patients without macrovascular disease. [29.0% (20/69) vs. 44.2% (19/43)]. CONCLUSION/
INTERPRETATION: This study confirms a trendwise association of PlA2 with severe coronary artery disease, but rather suggests an even stronger, highly significant association with the metabolic condition of Type 2 diabetes mellitus. This justifies the speculation that pathways dependent on the platelet alpha(2)beta(3) integrin physiology could be implicated in the pathogenesis of Type 2 diabetes which lends further support to the "common soil" hypothesis of diabetes and vascular disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12827240     DOI: 10.1007/s00125-003-1132-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  40 in total

1.  Inhibition of calpain blocks platelet secretion, aggregation, and spreading.

Authors:  K Croce; R Flaumenhaft; M Rivers; B Furie; B C Furie; I M Herman; D A Potter
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

Review 2.  Defective nitric oxide synthesis: a link between metabolic insulin resistance, sympathetic overactivity and cardiovascular morbidity.

Authors:  U Scherrer; C Sartori
Journal:  Eur J Endocrinol       Date:  2000-04       Impact factor: 6.664

Review 3.  Calpain regulation of integrin alpha IIb beta 3 signaling in human platelets.

Authors:  S M Schoenwaelder; Y Yuan; S P Jackson
Journal:  Platelets       Date:  2000-06       Impact factor: 3.862

Review 4.  The molecular immunology of human platelet proteins.

Authors:  T J Kunicki; P J Newman
Journal:  Blood       Date:  1992-09-15       Impact factor: 22.113

5.  The role of calpain in stimulus-response coupling: evidence that calpain mediates agonist-induced expression of procoagulant activity in platelets.

Authors:  J E Fox; C C Reynolds; C D Austin
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

Review 6.  Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence.

Authors:  E J Topol
Journal:  Circulation       Date:  1998-01-20       Impact factor: 29.690

7.  Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus.

Authors:  Y Horikawa; N Oda; N J Cox; X Li; M Orho-Melander; M Hara; Y Hinokio; T H Lindner; H Mashima; P E Schwarz; L del Bosque-Plata; Y Horikawa; Y Oda; I Yoshiuchi; S Colilla; K S Polonsky; S Wei; P Concannon; N Iwasaki; J Schulze; L J Baier; C Bogardus; L Groop; E Boerwinkle; C L Hanis; G I Bell
Journal:  Nat Genet       Date:  2000-10       Impact factor: 38.330

8.  A monoclonal antibody (SZ21) specific for platelet GPIIIa distinguishes P1A1 from P1A2.

Authors:  E J Weiss; P J Goldschmidt-Clermont; D Grigoryev; Y Jin; T S Kickler; P F Bray
Journal:  Tissue Antigens       Date:  1995-11

9.  Gene frequencies of the five major human platelet antigens in African American, white, and Korean populations.

Authors:  H O Kim; Y Jin; T S Kickler; K Blakemore; O H Kwon; P F Bray
Journal:  Transfusion       Date:  1995-10       Impact factor: 3.157

10.  A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis.

Authors:  E J Weiss; P F Bray; M Tayback; S P Schulman; T S Kickler; L C Becker; J L Weiss; G Gerstenblith; P J Goldschmidt-Clermont
Journal:  N Engl J Med       Date:  1996-04-25       Impact factor: 91.245

View more
  9 in total

1.  Author reply to Reiger et. al. commentary on Genetic variation of the platelet- surface integrin GPIIb-IIIa (PIA1/A2-SNP) shows a high association with Type 2 diabetes mellitus.Diabetologia. 2003 Jul;46(7):984-9.

Authors:  D Tschoepe
Journal:  Diabetologia       Date:  2004-05-07       Impact factor: 10.122

2.  Platelet glycoprotein IIIA PIA2 polymorphism is associated with ST elevation acute myocardial infarction in young Mexican population.

Authors:  David Santiago-Germán; Alfredo Leaños-Miranda; Ethel García-Latorre; Gabriela Borrayo-Sánchez; Abraham Majluf-Cruz; Irma Isordia-Salas
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

3.  The PlA1/A2 polymorphism of platelet glycoprotein IIIa is not associated with the risk of type 2 diabetes. The Ludwigshafen Risk and Cardiovascular Health study.

Authors:  W März; B O Boehm; B R Winkelmann; M M Hoffmann
Journal:  Diabetologia       Date:  2004-11-24       Impact factor: 10.122

4.  Association of platelet ITGA2B and ITGB3 polymorphisms with ex vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.

Authors:  Mu-Peng Li; Yan Xiong; An Xu; Ji-Peng Zhou; Jie Tang; Zan-Ling Zhang; Hong-Hao Zhou; Wei Zhang; Xiao-Ping Chen
Journal:  Int J Hematol       Date:  2014-01-29       Impact factor: 2.490

5.  The a1/a2 polymorphism of the glycoprotein IIIa gene and myocardial infarction in Caucasians with type 2 diabetes.

Authors:  Jovana Nikolajević-Starčević; Daniel Petrovič
Journal:  Mol Biol Rep       Date:  2012-11-27       Impact factor: 2.316

6.  Functional annotation and enrichment analysis of differentially expressed serum proteins in patients with type 2 diabetes after dapagliflozin.

Authors:  Yan-Xue Zhao; Sarul Borjigin; Zhao-Li Yan
Journal:  World J Diabetes       Date:  2022-03-15

7.  β3-integrin Leu33Pro gain of function variant does not modulate inflammatory activity in human derived macrophages in diabetes.

Authors:  Philipp Helmer; Ellen Damm; Stephan Schiekofer; Kirsten Roomp; Jochen G Schneider
Journal:  Int J Med Sci       Date:  2021-05-13       Impact factor: 3.738

8.  Increased Prevalence of Glycoprotein IIb/IIIa Leu 33 Pro Polymorphism in End Stage Renal Disease Patients on Hemodialysis.

Authors:  Amein Al-Ali; Fahad Al-Muhanna; Samir Al-Mueilo; Emmanuel Larbi; Ali Al-Sultan; Abdullah Rubaish; Suad Al-Ateeq; Alhusain Al-Zaharani
Journal:  Int J Biomed Sci       Date:  2008-09

9.  PLA1A2 platelet polymorphism predicts mortality in prediabetic subjects of the population based KORA S4-Cohort.

Authors:  Bernd Stratmann; Tao Xu; Christa Meisinger; Barbara Menart; Michael Roden; Christian Herder; Harald Grallert; Annette Peters; Wolfgang Koenig; Thomas Illig; Heinz-Erich Wichmann; Rui Wang-Sattler; Wolfgang Rathmann; Diethelm Tschoepe
Journal:  Cardiovasc Diabetol       Date:  2014-05-05       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.